These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23965883)

  • 1. [Long-term outcomes and factors for predicting ventricular arrhythmia in patients with catecholaminergic polymorphic ventricular tachycardia].
    Yu SY; Shen JH; Lu JP; Zhao DS; Zhang G; Geng J; Shan QJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Aug; 15(8):671-7. PubMed ID: 23965883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. U-waves and T-wave peak to T-wave end intervals in patients with catecholaminergic polymorphic ventricular tachycardia, effects of beta-blockers.
    Viitasalo M; Oikarinen L; Väänänen H; Kontula K; Toivonen L; Swan H
    Heart Rhythm; 2008 Oct; 5(10):1382-8. PubMed ID: 18929323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mid-term clinical condition and prognosis in adrenergic ventricular tachycardia in children with apparently normal hearts].
    Drago F; Vignati G; Agostino DA; Mauri L; Calzolari A; Figini A; Ragonese P
    G Ital Cardiol; 1997 Apr; 27(4):349-56. PubMed ID: 9244739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical features of six patients with catecholaminergic polymorphic ventricular tachycardia].
    Zhao DS; Shen JH; Lu JP; Yu SY; Zhang G; Geng J; Shan QJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Oct; 40(10):844-8. PubMed ID: 23302672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands.
    Hayashi M; Denjoy I; Hayashi M; Extramiana F; Maltret A; Roux-Buisson N; Lupoglazoff JM; Klug D; Maury P; Messali A; Guicheney P; Leenhardt A
    Europace; 2012 Sep; 14(9):1344-51. PubMed ID: 22383456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Claudio B; Alice M; Daniel S
    Mini Rev Med Chem; 2018; 18(6):476-482. PubMed ID: 28685702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical and Psychological Consequences of Left Cardiac Sympathetic Denervation in Long-QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia.
    Waddell-Smith KE; Ertresvaag KN; Li J; Chaudhuri K; Crawford JR; Hamill JK; Haydock D; Skinner JR;
    Circ Arrhythm Electrophysiol; 2015 Oct; 8(5):1151-8. PubMed ID: 26224781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening.
    Haugaa KH; Leren IS; Berge KE; Bathen J; Loennechen JP; Anfinsen OG; Früh A; Edvardsen T; Kongsgård E; Leren TP; Amlie JP
    Europace; 2010 Mar; 12(3):417-23. PubMed ID: 20106799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
    Rosso R; Kalman JM; Rogowski O; Diamant S; Birger A; Biner S; Belhassen B; Viskin S
    Heart Rhythm; 2007 Sep; 4(9):1149-54. PubMed ID: 17765612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments.
    van der Werf C; Zwinderman AH; Wilde AA
    Europace; 2012 Feb; 14(2):175-83. PubMed ID: 21893508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
    Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
    Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catecholaminergic polymorphic ventricular tachycardia with associated sinus node dysfunction.
    Joshi P; Saxena A; Kaul U; Mansoor AH
    Indian Heart J; 2010; 62(1):84-6. PubMed ID: 21180045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
    Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
    Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination of celiprolol and amiodarone in the treatment of recurrent ventricular tachycardia].
    Tonet J; Hidden F; Naditch L; Coutte R; Himbert C; Frank R
    Ann Cardiol Angeiol (Paris); 1996 Jan; 45(1):18-23. PubMed ID: 8815771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
    Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
    JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate.
    Miyake CY; Webster G; Czosek RJ; Kantoch MJ; Dubin AM; Avasarala K; Atallah J
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):579-87. PubMed ID: 23667268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.
    Leren IS; Saberniak J; Majid E; Haland TF; Edvardsen T; Haugaa KH
    Heart Rhythm; 2016 Feb; 13(2):433-40. PubMed ID: 26432584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal sympathetic denervation assisted treatment of electrical storm due to polymorphic ventricular tachycardia in a patient with cathecolaminergic polymorphic ventricular tachycardia.
    Aksu T; Güler TE; Özcan KS; Bozyel S; Yalın K
    Turk Kardiyol Dern Ars; 2017 Jul; 45(5):441-449. PubMed ID: 28694398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death.
    Sumitomo N; Harada K; Nagashima M; Yasuda T; Nakamura Y; Aragaki Y; Saito A; Kurosaki K; Jouo K; Koujiro M; Konishi S; Matsuoka S; Oono T; Hayakawa S; Miura M; Ushinohama H; Shibata T; Niimura I
    Heart; 2003 Jan; 89(1):66-70. PubMed ID: 12482795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ventricular tachycardia and exercise related syncope in children with structurally normal hearts: emphasis on repolarisation abnormality.
    Noh CI; Song JY; Kim HS; Choi JY; Yun YS
    Br Heart J; 1995 Jun; 73(6):544-7. PubMed ID: 7626354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.